422 related articles for article (PubMed ID: 25205329)
1. Five-grass-pollen sublingual immunotherapy tablet for the treatment of grass-pollen-induced allergic rhinoconjunctivitis: 5 years of experience.
Didier A; Wahn U; Horak F; Cox LS
Expert Rev Clin Immunol; 2014 Oct; 10(10):1309-24. PubMed ID: 25205329
[TBL] [Abstract][Full Text] [Related]
2. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
[TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability of 5-grass pollen tablet sublingual immunotherapy: pooled analysis and clinical review.
Didier A; Bons B
Expert Opin Drug Saf; 2015 May; 14(5):777-88. PubMed ID: 25732009
[TBL] [Abstract][Full Text] [Related]
4. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis.
Dahl R; Stender A; Rak S
Allergy; 2006 Feb; 61(2):185-90. PubMed ID: 16409194
[TBL] [Abstract][Full Text] [Related]
5. Management of Grass Pollen Allergy with 5-Grass Pollen Tablet: Results of a 2-Year Real-Life Study.
Shah-Hosseini K; Krudewig EM; Hadler M; Karagiannis E; Mösges R
Adv Ther; 2017 Jun; 34(6):1382-1397. PubMed ID: 28455783
[TBL] [Abstract][Full Text] [Related]
6. Sublingual Immunotherapy with a Five-Grass Pollen Tablet in Adult Patients with Allergic Rhinitis: An Open, Prospective, Noninterventional, Multicenter Study.
Pfaar O; Richter HG; Klimek L; Sieber J; Hadler M; Karagiannis E
Biomed Res Int; 2015; 2015():584291. PubMed ID: 26351635
[TBL] [Abstract][Full Text] [Related]
7. Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis.
Didier A; Malling HJ; Worm M; Horak F; Sussman G; Melac M; Soulié S; Zeldin RK
Clin Exp Allergy; 2013 May; 43(5):568-77. PubMed ID: 23600548
[TBL] [Abstract][Full Text] [Related]
8. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis.
Didier A; Worm M; Horak F; Sussman G; de Beaumont O; Le Gall M; Melac M; Malling HJ
J Allergy Clin Immunol; 2011 Sep; 128(3):559-66. PubMed ID: 21802126
[TBL] [Abstract][Full Text] [Related]
9. SQ grass sublingual allergy immunotherapy tablet for disease-modifying treatment of grass pollen allergic rhinoconjunctivitis.
Dahl R; Roberts G; de Blic J; Canonica GW; Kleine-Tebbe J; Nolte H; Lawton S; Nelson HS
Allergy Asthma Proc; 2016; 37(2):92-104. PubMed ID: 26802643
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen induced rhinoconjunctivitis - a Northern European perspective.
Bachert C; Vestenbaek U; Christensen J; Griffiths UK; Poulsen PB
Clin Exp Allergy; 2007 May; 37(5):772-9. PubMed ID: 17456225
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunological changes during sublingual immunotherapy with standardized quality grass allergen tablets.
Malling HJ; Lund L; Ipsen H; Poulsen L
J Investig Allergol Clin Immunol; 2006; 16(3):162-8. PubMed ID: 16784009
[TBL] [Abstract][Full Text] [Related]
12. Allergy immunotherapy tablet: Grazax® for the treatment of grass pollen allergy.
Senna GE; Calderon M; Milani M
Expert Rev Clin Immunol; 2011 Jan; 7(1):21-7. PubMed ID: 21162646
[TBL] [Abstract][Full Text] [Related]
13. Oralair(®): a causal treatment for grass pollen-induced allergic rhinoconjunctivitis.
Köberlein J; Mösges R
Immunotherapy; 2013 Jan; 5(1):13-21. PubMed ID: 23256794
[TBL] [Abstract][Full Text] [Related]
14. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
[TBL] [Abstract][Full Text] [Related]
15. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial.
Kleine-Tebbe J; Ribel M; Herold DA
Allergy; 2006 Feb; 61(2):181-4. PubMed ID: 16409193
[TBL] [Abstract][Full Text] [Related]
16. Lack of effect of Timothy grass pollen sublingual immunotherapy tablet on birch pollen-induced allergic rhinoconjunctivitis in an environmental exposure unit.
Ellis AK; Tenn MW; Steacy LM; Adams DE; Day AG; Walker TJ; Nolte H
Ann Allergy Asthma Immunol; 2018 May; 120(5):495-503.e2. PubMed ID: 29432967
[TBL] [Abstract][Full Text] [Related]
17. Update about Oralair® as a treatment for grass pollen allergic rhinitis.
Klimek L; Brehler R; Mösges R; Demoly P; Mullol J; Wang DY; O'Hehir RE; Didier A; Kopp M; Bos C; Karagiannis E
Hum Vaccin Immunother; 2022 Nov; 18(5):2066424. PubMed ID: 35704772
[TBL] [Abstract][Full Text] [Related]
18. Optimum treatment strategies for polyallergic patients - analysis of a large observational trial.
Shah-Hosseini K; Mioc K; Hadler M; Karagiannis E; Mösges R
Curr Med Res Opin; 2015 Dec; 31(12):2249-59. PubMed ID: 26366617
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE.
Cox LS; Casale TB; Nayak AS; Bernstein DI; Creticos PS; Ambroisine L; Melac M; Zeldin RK
J Allergy Clin Immunol; 2012 Dec; 130(6):1327-34.e1. PubMed ID: 23122534
[TBL] [Abstract][Full Text] [Related]
20. 300IR 5-Grass pollen sublingual tablet offers relief from nasal symptoms in patients with allergic rhinitis.
Serrano E; Wahn HU; Didier A; Bachert C
Am J Rhinol Allergy; 2014; 28(6):471-6. PubMed ID: 25335122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
